Direct-to-consumer advertisements continue to urge patients who take warfarin for atrial fibrillation to ask their doctors about the benefits of one or another of the newer anticoagulants. This review (Medical Letter, April 11) addresses the efficacy, bleeding and reversibility of direct oral anticoagulants. The article concludes that “the direct oral anticoagulants dabigatran (Pradaxa), apixaban (Eliquis), eoxaban (Savaysa, and rivaroxaban (Zarelto) have been at least as effective as warfarin (Coumadin, and others) in preventing stroke or systemic embolism in patients with nonvalvular atrial fibrillation, and they may appear to be safer. Patients well-controlled on warfarin (INR stable in the therapeutic range) could stay on it. For all others, one of the direct oral anticoagulants might be a better choice. Head-to-head comparisons of the new drugs are lacking.” Click here to read full text.